TDSG.F Stock Overview
A molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.07 |
| 52 Week High | CA$0.19 |
| 52 Week Low | CA$0.069 |
| Beta | 1.04 |
| 11 Month Change | -20.81% |
| 3 Month Change | -56.33% |
| 1 Year Change | -53.64% |
| 33 Year Change | -76.67% |
| 5 Year Change | -52.38% |
| Change since IPO | -97.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| TDSG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.2% | 2.4% | 2.2% |
| 1Y | -53.6% | 16.2% | 31.7% |
Return vs Industry: TDSG.F underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: TDSG.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| TDSG.F volatility | |
|---|---|
| TDSG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine TDSG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients.
Telo Genomics Corp. Fundamentals Summary
| TDSG.F fundamental statistics | |
|---|---|
| Market cap | US$5.87m |
| Earnings (TTM) | -US$1.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs TDSG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TDSG.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.71m |
| Earnings | -CA$2.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TDSG.F perform over the long term?
See historical performance and comparison